Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H16N3O14P3 |
| Molecular Weight | 483.1563 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H]2O
InChI
InChIKey=PCDQPRRSZKQHHS-CCXZUQQUSA-N
InChI=1S/C9H16N3O14P3/c10-5-1-2-12(9(15)11-5)8-7(14)6(13)4(24-8)3-23-28(19,20)26-29(21,22)25-27(16,17)18/h1-2,4,6-8,13-14H,3H2,(H,19,20)(H,21,22)(H2,10,11,15)(H2,16,17,18)/t4-,6-,7+,8-/m1/s1
Elacytarabine (CP-4055 or araC-5'elaidic acid ester) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine blocks cell division and may kill cancer cells. It is a type of antimetabolite. It was studied in clinical trials for the treatment of solid tumors. In preclinical and clinical studies, elacytarabine has demonstrated both safety and efficacy in acute myeloid leukemia (AML), with noteworthy activity among the cytarabine-refractory AML population. Elacytarabine was granted orphan drug designation status from the European Commission in 2007 and from the US FDA in 2008, with a fast-track approval designation from the FDA in 2010. Elacytarabine development has been discontinued.
Originator
Approval Year
Sample Use Guides
Thirty-four patients (19 malignant melanoma, 8 ovarian cancers and 7 NSCLC) received CP-4055 as a 30 min, or 2 hr intravenous (IV) infusion daily for 5 consecutive days every 3 or 4 weeks (D1-5 q3w or D1-5 q4w) in a dose escalation designed study with doses ranging from 30 to 240 mg/m(2)/day.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C709
Created by
admin on Sat Dec 16 09:55:45 GMT 2023 , Edited by admin on Sat Dec 16 09:55:45 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
S78SFW950O
Created by
admin on Sat Dec 16 09:55:45 GMT 2023 , Edited by admin on Sat Dec 16 09:55:45 GMT 2023
|
PRIMARY | |||
|
C105950
Created by
admin on Sat Dec 16 09:55:45 GMT 2023 , Edited by admin on Sat Dec 16 09:55:45 GMT 2023
|
PRIMARY | |||
|
13191-15-6
Created by
admin on Sat Dec 16 09:55:45 GMT 2023 , Edited by admin on Sat Dec 16 09:55:45 GMT 2023
|
PRIMARY | |||
|
DTXSID40927388
Created by
admin on Sat Dec 16 09:55:45 GMT 2023 , Edited by admin on Sat Dec 16 09:55:45 GMT 2023
|
PRIMARY | |||
|
25774
Created by
admin on Sat Dec 16 09:55:45 GMT 2023 , Edited by admin on Sat Dec 16 09:55:45 GMT 2023
|
PRIMARY | |||
|
Arabinofuranosylcytosine triphosphate
Created by
admin on Sat Dec 16 09:55:45 GMT 2023 , Edited by admin on Sat Dec 16 09:55:45 GMT 2023
|
PRIMARY |
PARENT (METABOLITE ACTIVE)
SUBSTANCE RECORD
